Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory mechanism study without human clinical trial or epidemiological cohort data reported
PubMed 32697943 · doi:10.1016/j.cmet.2020.07.007
What was done
In vitro mechanistic study examining how elevated glucose and SARS-CoV-2 infection alter the metabolic activity of monocytes and macrophages, specifically evaluating the role of mitochondrial reactive oxygen species (ROS) and hypoxia-inducible factor-1α (HIF-1α) stabilization.
What was found
The abstract reports no numerical values or effect estimates. SARS-CoV-2 infection induced mitochondrial ROS, stabilizing HIF-1α and driving glycolysis in monocytes, which facilitated viral replication. This altered monocyte metabolism directly inhibited T cell responses and reduced epithelial cell survival.
Why it matters
It provides a cellular mechanism explaining why diabetic individuals with uncontrolled blood glucose experience worse COVID-19 outcomes, suggesting the HIF-1α/glycolysis axis as a drug target.
Limits
The study is restricted to in vitro bench research. The abstract provides no human clinical outcome data, patient sample sizes, or quantitative effect sizes.
Cited by
- supports SARS-CoV-2 replicates more efficiently in a glycolytic environment.